Role of lifestyle factors on plasma homocysteine levels in Parkison's disease patients treated with levodopa

被引：17
|
作者：
Siniscalchi, Antonio
Gallelli, Luca
Mercuri, Nicola B.
Ibbadu, Guido Ferreri
De Sarro, Giovambattista
机构：
[1] Mater Domini Univ Hosp, Fac Med & Surg Univ Magna Grecia, Dept Expt & Clin Med, Clin Pharmacol Unit, Catanzaro, Italy
[2] Annunziata Hosp, Dept Neurosci, Div Neurol, Cosenza, Italy
[3] Univ Roma Tor Vergata, IRCCS S Lucia, Rome, Italy
[4] Univ Roma Tor Vergata, Dept Neurol, Rome, Italy
来源：
NUTRITIONAL NEUROSCIENCE | 2006年 / 9卷 / 1-2期
关键词：
homocysteine; Parkinson's disease patients; vitamin; coffee; smoke; behaviours;
D O I：
10.1080/10284150600583446
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
Many papers documented that Parkinson's disease (PD) patients treated with levodopa (L-dopa) shows elevated plasma homocysteine (Hcy) levels. Several lifestyle factors are able to influence plasma Hcy levels. We review the evidence that L-dopa therapy is related with an increase in plasma Hcy levels and that several behaviours could be able to cause changes in plasma Hcy concentrations. Therefore, there are reasons to suggest that a healthy lifestyle lowering Hcy may prevent this potential iatrogenic complication during L-dopa therapy. Moreover, at present, no controlled prospective studies have evaluated this phenomenon.
引用
收藏
页码：11 / 16
页数：6
相关论文
共 50 条
  • [1] Elevated plasma homocysteine levels in patients treated with levodopa - Association with vascular disease
    Rogers, JD
    Sanchez-Saffon, A
    Frol, AB
    Diaz-Arrastia, R
    [J]. ARCHIVES OF NEUROLOGY, 2003, 60 (01) : 59 - 64
  • [2] Entacapone significantly decreases elevated plasma homocysteine levels in levodopa-treated Parkinson's disease patients
    Nissinen, H
    Ellmen, J
    Vahteristo, M
    [J]. MOVEMENT DISORDERS, 2005, 20 : S94 - S94
  • [3] Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients
    Valkovic, P
    Benetin, J
    Blazicek, P
    Valkovicová, L
    Gmitterová, K
    Kukumberg, P
    [J]. PARKINSONISM & RELATED DISORDERS, 2005, 11 (04) : 253 - 256
  • [4] Plasma homocysteine levels in patients treated with levodopa: motor and cognitive associations
    Ozer, Feriha
    Meral, Hasan
    Hanoglu, Lutfu
    Aydemir, Tuba
    Yilsen, Meral
    Cetin, Sibel
    Ozturk, Oya
    Seval, Hatice
    Koldas, Macit
    [J]. NEUROLOGICAL RESEARCH, 2006, 28 (08) : 853 - 858
  • [5] Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients
    Nevrly, M.
    Kanovsky, P.
    Vranova, H.
    Langova, K.
    Hlustik, P.
    [J]. PARKINSONISM & RELATED DISORDERS, 2009, 15 (06) : 477 - 478
  • [6] Plasma homocysteine levels in idiopathic Parkinson's disease: Role of idiopathic Parkinson's disease and levodopa treatment
    Flat, S. -W.
    Kim, J. -M.
    Cho, J. -S.
    Cho, E. -K.
    [J]. PARKINSONISM & RELATED DISORDERS, 2007, 13 : S116 - S116
  • [7] Investigation of plasma homocysteine in patients with Parkinson's disease, treated with levodopa and in those treated with other medications
    Todorova, A. T.
    [J]. MOVEMENT DISORDERS, 2008, 23 (01) : S307 - S308
  • [8] Plasma homocysteine levels in pergolide treated Parkinson's disease patients
    Ozkan, S
    Colak, O
    Kutlu, C
    Ertan, M
    Alatas, O
    [J]. MOVEMENT DISORDERS, 2004, 19 : S388 - S389
  • [9] Elevation of total homocysteine levels in patients with Parkinson's disease treated with duodenal levodopa/carbidopa gel
    Mueller, Thomas
    Jugel, Constanze
    Ehret, Reinhard
    Ebersbach, Georg
    Bengel, Gunar
    Muhlack, Siegfried
    Klostermann, Fabian
    [J]. JOURNAL OF NEURAL TRANSMISSION, 2011, 118 (09) : 1329 - 1333
  • [10] Elevation of total homocysteine levels in patients with Parkinson’s disease treated with duodenal levodopa/carbidopa gel
    Thomas Müller
    Constanze Jugel
    Reinhard Ehret
    Georg Ebersbach
    Gunar Bengel
    Siegfried Muhlack
    Fabian Klostermann
    [J]. Journal of Neural Transmission , 2011, 118 : 1329 - 1333
12345